Home DailyMed f8fbcae7-4b18-4551-9a56-36746cf8c3bd National Council for Prescription Drug Programs indexing - billing unit Drug label information. FDA.report displays public Structured Product Labeling data from DailyMed and legacy FDA.report DailyMed cache rows. This page is not medical advice, prescribing advice, or a substitute for the official label reviewed by a qualified healthcare professional. Labeling can change; when a current hydrated DailyMed SPL record is available, FDA.report shows that newer record before legacy cached files.
Manufacturer National Council for Prescription Drug Programs
Effective date 2013-03-03
Label type Indexing - Billing Unit
Version 1
Source full-release
Hydrated at 2026-06-05 04:03:09 Orange Book application contexts# All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book application contexts page 1 of 1 · 1 matching rows.
Source provenance: Browse the complete Orange Book source catalog .
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N022529-001 BELVIQ 10MG TABLET / ORAL RLD, RS 2012-06-27 74a2ff9319b5…2021-03-12 10:30 UTC 2021-03 N022529-001 BELVIQ 10MG TABLET / ORAL RLD 2012-06-27 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N022529-001 BELVIQ 10MG TABLET / ORAL RLD 2012-06-27 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N022529-001 BELVIQ 10MG TABLET / ORAL RLD 2012-06-27 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N022529-001 BELVIQ 10MG TABLET / ORAL RLD, RS 2012-06-27 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N022529-001 BELVIQ 10MG TABLET / ORAL RLD, RS 2012-06-27 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N022529-001 BELVIQ 10MG TABLET / ORAL RLD, RS 2012-06-27 ea99ee380514…
Observed Orange Book patent history# Patent history page 1 of 8 · 294 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N022529-001 6953787 2023-04-10 U-1255 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 6953787 2023-04-10 U-1253 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 6953787 2023-04-10 U-1254 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 6953787 2023-04-10 U-1252 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7514422 2023-04-10 U-1255 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7514422 2023-04-10 U-1254 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7514422 2023-04-10 U-1252 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7514422 2023-04-10 U-1253 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7977329 2023-04-10 U-1254 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7977329 2023-04-10 U-1252 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7977329 2023-04-10 U-1255 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 7977329 2023-04-10 U-1253 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8207158 2023-04-10 U-1254 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8207158 2023-04-10 U-1252 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8207158 2023-04-10 U-1255 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8207158 2023-04-10 U-1253 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8273734 2023-04-10 U-1254 2012-10-23 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8273734 2023-04-10 U-1255 2012-10-23 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8367657 2023-04-10 U-1254 Drug substance, Drug product 2013-03-01 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8367657 2023-04-10 U-1253 Drug substance, Drug product 2013-03-01 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8367657 2023-04-10 U-1252 Drug substance, Drug product 2013-03-01 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8367657 2023-04-10 U-1255 Drug substance, Drug product 2013-03-01 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8546379 2023-04-10 U-1252 Drug substance, Drug product 2013-10-25 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8546379 2023-04-10 U-1254 Drug substance, Drug product 2013-10-25 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8546379 2023-04-10 U-1253 Drug substance, Drug product 2013-10-25 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8546379 2023-04-10 U-1255 Drug substance, Drug product 2013-10-25 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8575149 2023-04-10 U-1452 2013-12-04 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8946207 2024-06-16 Drug product 2015-03-03 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8697686 2025-12-20 Drug substance, Drug product 2014-05-13 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8980881 2025-12-20 U-1253 2015-04-15 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8980881 2025-12-20 U-1252 2015-04-15 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8980881 2025-12-20 U-1255 2015-04-15 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8980881 2025-12-20 U-1254 2015-04-15 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8168624 2029-04-18 Drug substance, Drug product 2012-07-24 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 9770455 2031-08-31 U-2110 2017-09-26 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 9169213 2032-12-06 U-1762 2015-11-12 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 9169213 2032-12-06 U-1764 2015-11-12 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 9169213 2032-12-06 U-1763 2015-11-12 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 9169213 2032-12-06 U-1765 2015-11-12 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022529-001 8999970 2033-02-07 U-1692 2015-05-07 74a2ff9319b5…
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.